4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
13 citations
,
December 2013 in “Chemistry Central Journal” Sunlight exposure increases drug toxicity; amber glass best for protection.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
1 citations
,
January 2013 in “PubMed” Adenosine led to higher patient satisfaction than minoxidil for hair loss treatment.
February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
1 citations
,
January 2025 in “Dermatologic Therapy” Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.
March 2026 in “Pharmaceuticals” Reporter characteristics affect detection of hair loss from cancer therapy.
August 2024 in “medRxiv (Cold Spring Harbor Laboratory)” Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
14 citations
,
January 2015 in “Acta dermato-venereologica” Acitretin significantly reduced inflammatory attacks in a woman with Naevus Comedonicus Syndrome but caused side effects.
February 2010 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Finasteride can cause skin reactions, so dermatologists should be aware.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
6 citations
,
April 2013 in “Journal of Investigative Dermatology” Spironolactone might lower the chance of getting rosacea.
3 citations
,
February 1985 in “PubMed” Stopping the beta-blocker nadolol led to quick hair regrowth and improved scalp condition.
40 citations
,
January 2017 in “Intestinal Research” Genotyping for NUDT15 p.Arg139Cys can help predict thiopurine side effects in Japanese IBD patients.
6 citations
,
October 2013 in “Expert Review of Dermatology” Psychotropic medications can cause skin problems, including serious conditions, and patients should be monitored closely.
4 citations
,
February 2013 in “Revista De Saude Publica” Pill organizers and cutters can help with taking medication regularly but may affect the medication's effectiveness and safety.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
3 citations
,
August 2020 in “Urology Journal” Using 5-alpha reductase inhibitors may increase the risk of mild depression.
22 citations
,
December 2018 in “British Journal of Clinical Pharmacology” HPV vaccines are generally safe but need further investigation for rare side effects.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
14 citations
,
October 1977 in “The Lancet”